[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597569":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":10,"centralContacts":39,"locations":45,"responsibleParty":58,"collaborators":10,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":77,"studyType":78,"phases":10,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":86,"whyStopped":10,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Democritus University of Thrace","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Control Group",null,"Healthy controls",[13,14,15],"Diagnostic Test: Distant Visual Acuity","Diagnostic Test: Optical Coherence Tomography","Diagnostic Test: Optical Coherence Tomography Angiography",{"label":17,"type":10,"description":18,"interventionNames":19},"AMD Patients","Patients with AMD stage 9 in both eyes.",[13,14,15,20],"Diagnostic Test: Autofluorescence imaging",[22,27,31,35],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"DIAGNOSTIC_TEST","Distant Visual Acuity","Distant Visual acuity of all participants using DDART web-application monocularly in both eyes.",[17,9],{"type":23,"name":28,"description":29,"armGroupLabels":30,"otherNames":10},"Optical Coherence Tomography","Optical Coherence Tomography of the macula will be performed to all patients.",[17,9],{"type":23,"name":32,"description":33,"armGroupLabels":34,"otherNames":10},"Optical Coherence Tomography Angiography","Optical Coherence Tomography Angiography of the macula will be performed to all patients.",[17,9],{"type":23,"name":36,"description":37,"armGroupLabels":38,"otherNames":10},"Autofluorescence imaging","Autofluorescence imaging using fundus camera for AMD staging.",[17],[40],{"name":41,"role":42,"phone":43,"phoneExt":10,"email":44},"Minas Bakirtzis, MD, MSc","CONTACT","+302551030990","minas961@hotmail.com",[46],{"facility":47,"status":10,"city":48,"state":10,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":10},"University Hospital of Alexandroupolis","Alexandroupoli","68100","Greece","GR",{"type":53,"coordinates":54},"Point",[55,56],25.87644,40.84995,{"lat":56,"lon":55},{"type":59,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Georgios Labiris","Associate Professor of Ophthalmology","100597569","the-impact-of-artificial-lighting-on-the-visual-capacity-of-patients-with-age-related-macular-degeneration-100597569",false,"NCT07060196","The Impact of Artificial Lighting on the Visual Capacity of Patients With Age-Related Macular Degeneration","The Impact of Artificial Lighting on the Visual Capacity of Patients With Age-Related Macular Degeneration.","ADLs AMD","Inclusion Criteria:\n\n* Healthy controls over the age of 60.\n* Diagnosis of bilateral dry age-related macular degeneration (AMD).\n\nExclusion Criteria:\n\n* Patients with other ocular conditions such as high myopia, glaucoma, clinically significant diabetic retinopathy, and other diseases that may confound the evaluation of ocular outcome measurements.\n* Patients who have undergone intraocular surgeries, except for uncomplicated cataract extraction surgery performed at least 3 months prior to their inclusion in the study.\n* Individuals with systemic diseases, including oxalate kidney stones, Wilson's disease, hemochromatosis, lung cancer, or other illnesses associated with poor five-year survival.\n* Patients with binocular best-corrected distance visual acuity less than or equal to hand motion perception.\n* Patients with neurological, orthopedic, or psychiatric disorders that prevent them from completing the activities or conditions that may affect their performance.",true,"ALL","60 Years","100 Years",{"count":75,"type":76},70,"ESTIMATED","15 Days","OBSERVATIONAL","Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in the elderly worldwide. The dry, non-exudative form of the disease, although more common, is associated with gradual and significant decline in functional vision. Despite advancements in diagnostic and therapeutic approaches, a targeted intervention that improves the daily functionality of these patients is still lacking. One critical, yet often overlooked, factor that affects daily performance is lighting conditions.\n\nThis study aims to objectively assess the impact of different lighting intensity levels on patients with advanced dry AMD during the execution of everyday activities. A total of 60 individuals will be evaluated (30 healthy controls over 60 years of age and 30 patients with clinically diagnosed advanced AMD, according to NICE and AREDS criteria). Participants will undergo ophthalmological assessment (visual acuity, contrast sensitivity, OCT\u002FOCTA, autofluorescence), and their performance on five functional tasks (mobility, object grasping, sit-to-stand transition, obstacle avoidance, and hanging clothes) will be evaluated under eight lighting levels (20-300 lux) at a constant color temperature (4000K), in a specially designed laboratory equipped with motion and eye-tracking systems.\n\nThe primary endpoint is overall performance, based on task completion time and errors, expressed on a custom performance scale (0-100). Secondary data include changes in pupil size as an indicator of visual adaptation. The study aims to determine the optimal lighting range that maximizes functional vision and improves the quality of life for patients with AMD.",[81],"AMD - Age-Related Macular Degeneration",[83,84,85],"AMD","artificial lighting","ADLs","NOT_YET_RECRUITING","2025-07-08",{"date":89,"type":90},"2025-07-11","ACTUAL",{"date":92,"type":76},"2025-06-30",{"date":94,"type":76},"2027-01-31",{"name":5,"class":6},1]